News
TransNAT scientists’ insights into latest therapies for Duchenne muscular dystrophy.
5th December, 2023
In a review in the journal of Nature Reviews Drug Discovery, TransNAT investigators Thomas C. Roberts, Matthew J.A. Wood et al. from the University of Oxford discuss the latest Therapeutic approaches for the treatment of Duchenne muscular dystrophy.
Duchenne muscular dystrophy (DMD) is a genetic disorder characterised by the progressive loss of muscle, and one of the most severe forms of inherited muscular dystrophies.
In this review the authors discuss the drug development landscape for DMD with a main focus on dystrophin restoration therapies, and how these could pave the way to develop treatments for other genetic diseases with similar mechanisms of action.
To read more, find the citation here: